Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.

Drugs of today (Barcelona, Spain : 1998) - 1 Mar 2021

Gomaa A, Allam N, Waked I

Abstract excerpt

Effective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzimidazoles
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Valine

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 33729217
DOI: 10.1358/dot.2021.57.3.3251711

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.PMID 33729217Read ↗

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6.Semantic proximity Read ↗

Ideal oral combinations to eradicate HCV: The role of ribavirin.Semantic proximity Read ↗

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.Semantic proximity Read ↗

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity Read ↗

Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.Semantic proximity Read ↗

Pharmacology Update for the Treatment of Hepatitis C Virus.Semantic proximity Read ↗

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.Semantic proximity Read ↗

Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.Semantic proximity Read ↗

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.